The mutant coronavirus strain in the U.K. is highlighting how we need to invest in genomic sequencing. Dr. Nahid Bhadelia, Infectious Diseases Physician and Director of Special Pathogens at Boston Medical Center, joins Worldwide Exchange with her perspective on how…
The U.S. began vaccinating the population against the coronavirus earlier this month, but mass adoption is not a guarantee. Roughly four in ten Americans say they would “definitely” or “probably” not get a vaccine, according to a recent survey by…
Dr. Rey Panettieri, Rutgers Robert Wood Johnson Medical School professor of medicine, joins ‘Power Lunch’ to discuss Pfizer’s coronavirus vaccine and the concerns some people may have with it. For access to live and exclusive video from CNBC subscribe to…
#COVID19 #coronavirus #vaccines During this lecture we will be discussing COVID-19 vaccines including Moderna, Pfizer/BioNTech, and Astrazeneca/Oxford. We are NOT sponsored and/or endorsed by Moderna, Pfizer/BioNTech, or Astrazeneca. We are presenting on RESEARCH and in no way is any of…
Pharmaceutical giant Merck said it plans to acquire privately-held OncoImmune for $425 million in cash, gaining rights to an under-the-radar drug that’s shown striking results in hospitalized patients with Covid-19. Dr. Yang Liu, founder, CEO and chief scientific officer of…
The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly’s arthritis drug baricitinib, in combination with Gilead Sciences’ remdesivir, to treat Covid-19 patients. On Thursday, a WHO panel advised doctors against using remdesivir as a…
